PPARGC1A and acute myeloid leukemia: Survival analysis of 73 patients with AML (non‐M3 type) at West China Hospital also revealed that the median OS of patients with AML with high PGC‐1α expression was shorter than that of patients with low PGC‐1α expression (median OS 12.7 months vs. not reached, p = 0.0275) (Figure 7I), and there was no significant difference in EFS (median EFS 6.3 months vs. 10.0 months, p = 0.1168) (Figure 7J).